NeoGenomics Laboratories, Inc in Carlsbad operates a CLIA-certified oncology diagnostics facility on Salk Avenue as part of the Nasdaq-listed company's (NEO) national laboratory network. The Carlsbad lab processes next-generation sequencing panels alongside conventional FISH and flow cytometry, a testing depth that supports diagnostic pipelines fed by imaging referrals from SimonMed Imaging on the same biotech corridor. Founded in 2002, NeoGenomics maintains a menu of more than 500 oncology-focused assays covering solid tumors and hematologic malignancies across all major testing modalities. The company processes over 1.7 million cancer-related tests annually for approximately 4,400 clinical sites nationwide, including more than 100,000 NGS tests per year. Oncologists and pathologists order NeoGenomics panels to guide targeted therapy selection, complementing the diagnostic workups coordinated through Scripps Coastal Medical Center Carlsbad. The laboratory's FISH testing menu uses proprietary wet-lab processing to improve chromosomal resolution, and its flow cytometry panels include minimal residual disease detection calibrated below 10⁻⁴ sensitivity for post-treatment monitoring.